BeiGene (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

BeiGene ADR is working on a consolidation with a 248.16 entry. See if the stock can clear the breakout price in volume at ...

BEIGENE (06160.HK) announced that according to US GAAP, the company expects to achieve positive operating income for the full ...

BeiGene stock just hit that mark, with a jump from 69 to 84 Wednesday. Is BeiGene Stock A Buy? BeiGene stock reclaimed its 50 ...

BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.26 million.

Analyst Jill Wu of CMB International Securities maintained a Buy rating on BeiGene (ONC – Research Report), boosting the price target to ...

Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for antibody-drug conjugates (ADCs) and other assets in the final few days of ...

StockNews.com initiated coverage on shares of BeiGene (NASDAQ:BGNE – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock. Several other ...

BeiGene has won approval from the US Food and Drug Administration for its PD-1 inhibitor Tevimbra (tislelizumab) in combination with chemotherapy to treat advanced gastric or gastroesophageal ...

BeiGene said U.S. regulators had approved its Tevimbra to treat a form of stomach cancer. The oncology company said the Food and Drug Administration approved Tevimbra in combination with platinum ...

David Li, an analyst from Bank of America Securities, maintained the Hold rating on BeiGene (ONC – Research Report). The associated price ...